Prostate Cancer
Vaccine trials
Immunotherapy is being used as a experimental treatment for prostate cancer. Patients are injected with dead prostate cancer cells, so that the cells within the body responsible for protection against viruses and bacteria (the immune system) are alerted to the presence of cancer cells. If the treatment is successful, the cells in the immune system seek out and destroy any cells that resemble the tissues used in the vaccine. Two men described their experiences of vaccine trials.
Describes his experience of the vaccine trials.
Describes his experience of the vaccine trials.
SHOW TEXT VERSION
PRINT TRANSCRIPT
There were certain entry criteria for the trial that I had to fulfil. The main one was that I had to have a PSA of above 30 and rising and that I had to have had two hormone drugs that had ceased to work efficiently which I had. The only problem was that my PSA was just below 30 at that stage and wasn't rising so they said 'Well we can't take you until that happens.' So I had to start having regular monthly PSA tests until such time as my PSA went over 30 and carried on rising which eventually about 3 months later it did. So in July of last year I qualified for the trial and started on the trial. Because it was a trial things changed during it. I was originally told that we would have to go down to London every 4 weeks for the injections. The injections were 2 in the lymph nodes underneath the armpits and 2 in the groin at each side. That was okay, it wasn't too bad, there was just a slight stinging from the vaccine as it went in and then it was okay. Before the trial started I had to have some trial injections to find out if my skin would react to the vaccine at all and that was not the case, it didn't react so I was okay for going ahead with it. So we started work on the 4 weekly injections and I felt quite well, I felt my energy levels were increasing, I didn't feel as tired, I didn't feel as fatigued as I had done and I thought it was doing me good. I tried to get feedback from the consultant as to how they felt it was going but they were quite noncommittal, I think probably because it was a trial they didn't want to say too much about how they thought it was going. The only thing they did say was that they felt that the vast majority of men on the trial were feeling better and they seemed to be producing more cells to fight the cancer so that was encouraging news. And because I felt so well I assumed that I was one of the ones that was producing these cancer fighting cells.
Did they say much about how the vaccine had been developed and what was in it?
It was developed from dead cancer cells from other patients. There was a similar trial being conducted in America where the vaccine had been produced by taking the cells from the patients themselves but that was the difference between the two. I believe there's now a trial going on in Britain which does exactly the same thing as the American one where they take the dead cells from the cancer patients themselves, make the vaccine then re-inject it. There are currently additional trials going on as far as I'm aware, a new one at St George's, another one at Hammersmith Hospital in London. I don't know too much detail about those.
And how long does the trial go on for?
Well the trial, we were told initially that following 12 injections we were going to go down to 12 weekly injections but when it came to my turn to go onto the 12 weekly injections I was told that they'd changed their minds because they'd found that some of the men that had started before me were having adverse reactions to carrying on with the injections following the end of the 12, monthly ones. So they, they decided to change what they'd originally said and finished the vaccines after the 12 injections. So in July of this year I finished the injections. I immediately started having a reoccurrence of bone pain, whether that was because I'd stopped having the injections or whether it was coincidental I don't know.
Last reviewed July 2017.
Copyright © 2024 University of Oxford. All rights reserved.